Hepatocellular carcinoma, RhoGEF, sorafenib resistance, posttranslational modifications, HDAC2
Angiogenesis, Glutathione S-transferase zeta 1(GSTZ1), Oncometabolite Succinylacetone, PHD2, HIF-1α
COVID-19, post-exposure prophylaxis, antibody cocktail, nasal spray, clinical trial